Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases

NCT02633397 is registered in ClinicalTrials.gov with Mark Gladwin as lead sponsor.

NCT NCT02633397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02633397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Lead sponsor
Mark Gladwin
Phase
Phase 2
Overall status
Completed
Start date
April 11, 2017
Completion date
May 4, 2022
Enrollment
130 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease